Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study.
Therapeutic laquinimod treatment decreases inflammation, initiates axon remyelination, and improves motor deficit in a mouse model of multiple sclerosis.
Novartis updates US label on Gilenya® following discussions with the FDA
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.
Association between apolipoprotein E gene polymorphism and the risk of multiple sclerosis: A meta-analysis of 6977 subjects.
The initiation and prevention of multiple sclerosis.
Prospective Examination of Anxiety and Depression Before and During Confirmed and Pseudoexacerbations in Patients With Multiple Sclerosis.
Evaluation of oxidative and nitrosative stress in relapsing remitting multiple sclerosis: effect of corticosteroid therapy.
The role of growth factors as a therapeutic approach to demyelinating disease.
IL-1β induces hypomyelination in the periventricular white matter through inhibition of oligodendrocyte progenitor cell maturation via FYN/MEK/ERK signaling pathway in septic neonatal rats.
Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
MiR-126: a novel route for natalizumab action?
Accidental natalizumab administration to the third trimester of pregnancy in an adolescent patient with multiple sclerosis.
Safety and efficacy of fingolimod in treatment-naïve multiple sclerosis patients.
Twin studies and the heritability of MS: a conclusion.
Responder definition of the Multiple Sclerosis Impact Scale physical impact subscale for patients with physical worsening.
Painful Tonic Spasm in Neuromyelitis Optica: Incidence, Diagnostic Utility, and Clinical Characteristics.
Relationship between 25-OH-D serum level and relapse rate in multiple sclerosis patients before and after vitamin D supplementation.
Cladribine Exposure Results in a Sustained Modulation of the Cytokine Response in Human Peripheral Blood Mononuclear Cells.
Functional role of TRP channels in modulating ER stress and Autophagy.
A Multidimensional Computerized Adaptive Short-Form Quality of Life Questionnaire Developed and Validated for Multiple Sclerosis: The MusiQoL-MCAT.
What can we really tell women with multiple sclerosis regarding pregnancy? A systematic review and meta-analysis of the literature.
Postmarketing Safety Profile of Subcutaneous Interferon Beta-1a Given 3 Times Weekly: A Retrospective Administrative Claims Analysis.
Summary of evidence-based guideline: Complementary and alternative medicine in multiple sclerosis: Report of the Guideline Development Subcommittee of the American Academy of Neurology.
The olfactory vector hypothesis of neurodegenerative disease: is it viable?
Pages
« first
‹ previous
…
166
167
168
169
170
171
172
173
174
…
next ›
last »